Intra-Cellular Therapies Inc. Stock
We can see a decrease in the price for Intra-Cellular Therapies Inc.. Compared to yesterday it has lost -€1.000 (-1.460%).
With 23 Buy predictions and not a single Sell prediction Intra-Cellular Therapies Inc. is an absolute favorite of our community.
As a result the target price of 79 € shows a slightly positive potential of 17.04% compared to the current price of 67.5 € for Intra-Cellular Therapies Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Intra-Cellular Therapies Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Intra-Cellular Therapies Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intra-Cellular Therapies Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies Inc. | -1.460% | 0.000% | 7.656% | 21.841% | 3.528% | 166.377% | 549.913% |
| Ardelyx Inc. | -2.390% | -2.578% | -17.883% | 40.048% | 2.007% | -13.927% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | -2.727% | -46.500% | -69.209% | -22.883% | -98.244% | -99.994% |
| Brainstorm Cell | 1.170% | 3.754% | -21.032% | -81.975% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-11
Upon first glance, it appears that ITI (US symbol: ITCI), a company in the Biotechnology & Medical Research industry, exhibits a mix of positive and negative financial aspects. There has been a considerable growth in certain financial areas, while certain concerning trends are also observed in other areas.
*Pros: *
Growth in Total Assets: ITI has seen a notable growth in its total assets, with the year-end 2022 value at $754.78 million, up from $489.92 million in 2021 and $717.31 million in 2020. This indicates an expanding asset base, signaling growth and enhanced financial flexibility for the company.
Comments
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Show more
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $82.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $82.00 to $96.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ITCI provided by MarketBeat